This summary was created by AI, based on 55 opinions in the last 12 months.
Based on the reviews, experts have mixed opinions on Eli Lilly & Co. Some think it is a fantastic company with strong sales growth, leadership in the diet boom, and a diverse range of pharmaceutical products. Others are concerned about its high valuation, competition in the market, and potential uncertainty due to the new US administration. The stock has seen a great run in recent years, but there are varying opinions on its future potential.
Fantastic company. Leader in diet boom. Very high valuation - would recommend buying on weakness.
He continues to hold. 35x forward PE, 20% growth rate. Earnings and guidance somewhat disappointing. Long term, tremendous growth in obesity-treatment market and diabetes. Short term, watch technicals. Dipped below 200-day MA, but up $13-14 today. If it bounces here, may be attractive for new or additional money.
Got stopped out recently at $840. Below 200-day MA. RSI versus the market has rolled over. Backdrop for the pharma sector is behaving very poorly. He's going to wait and let the traffic clear.
They reported a miss. Weight-loss drugs have now swamped the market, thus shrinking margins. They trade at 80x PE vs. pharma's 12-14x. Why own this? Their PE is higher than even NVDA's. Their earlier super growth in GLP drugs is not sustainable.
He's surprised by today's plunge after reporting. A strong buy-the-dip today. He will give it the benefit of the doubt. Revenue growth in recent quarters has been sound.
It will go higher, but not much, and he wouldn't buy it now. Wait for a pullback.
We like LLY as a large pharmaceutical company, with strong sales growth driven by the high demand for its type 2 diabetes and chronic weight management medication. Analyst estimates call for strong forward sales and earnings growth, but a lot of this is priced into its valuation (51X forward earnings). LLY is an $821B market cap company, with strong margins and expected growth rates. It can be a volatile stock, but for a long-term hold, with a growth mindset in mind, we would be comfortable owning LLY today.
Unlock Premium - Try 5i Free
Healthcare space provides nice combination of growth with stability, in case we get into latter stage of economic cycle.
If owned he would trim but also would add on weakness. It is a little larger and more diversified than Novo-Nordisk.
Its moat are these giant factories they're building. It has firepower. Shares are up 52% this year. He remains a fan.
A great company and the leader in GLP drugs, but trades at a high 50x PE.
Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N
In the last year, 41 stock analysts published opinions about LLY-N. 26 analysts recommended to BUY the stock. 12 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..
Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
41 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.
On 2024-12-06, Eli Lilly & Co. (LLY-N) stock closed at a price of $826.71.
Don't buy here, even though valuation's come down. Big winner over the last 2 years. High profile, but single drug. Will start to face competition. New US administration may cause uncertainty. He'd rather pick up the laggards on cheap valuations. See his Top Picks.